NYSE:MYOV - Myovant Sciences News Headlines

Sign in or create an account to add this stock to your watchlist.
$12.43 -0.41 (-3.19 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$12.43
Today's Range$12.26 - $12.98
52-Week Range$11.65 - $27.45
Volume128,588 shs
Average Volume109,642 shs
Market Capitalization$880.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5

Headlines

Myovant Sciences (NYSE MYOV) News Headlines

Source:
DateHeadline
Myovant Sciences misses by $0.04Myovant Sciences misses by $0.04
seekingalpha.com - May 24 at 5:59 PM
Myovant plans to file U.S. application for relugolix in Q4Myovant plans to file U.S. application for relugolix in Q4
seekingalpha.com - May 24 at 5:59 PM
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal QuarterMyovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter
www.nasdaq.com - May 24 at 5:59 PM
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
finance.yahoo.com - May 24 at 5:59 PM
Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' pleaHealth Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
finance.yahoo.com - May 20 at 5:07 PM
Myovant Sciences Ltd.Myovant Sciences Ltd.
www.barrons.com - May 14 at 7:02 PM
Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding DrugMyovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug
finance.yahoo.com - May 14 at 7:02 PM
Roivant Statement on Positive Phase 3 Results from Myovants LIBERTY 1 Study in Uterine FibroidsRoivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroids
finance.yahoo.com - May 14 at 9:52 AM
Myovants relugolix successful in late-stage uterine fibroid study; shares up 2% premarketMyovant's relugolix successful in late-stage uterine fibroid study; shares up 2% premarket
seekingalpha.com - May 14 at 9:52 AM
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine FibroidsMyovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
finance.yahoo.com - May 14 at 9:52 AM
Introducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last YearIntroducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last Year
finance.yahoo.com - May 14 at 9:52 AM
Myovant Sciences uterine fibroids combo therapy meets main goal in studyMyovant Sciences' uterine fibroids combo therapy meets main goal in study
finance.yahoo.com - May 14 at 9:52 AM
Myovant stock up 1.6% after Phase 3 trial meets endpointsMyovant stock up 1.6% after Phase 3 trial meets endpoints
finance.yahoo.com - May 14 at 9:52 AM
Myovant to host conference call to discuss late-stage data on relugolixMyovant to host conference call to discuss late-stage data on relugolix
seekingalpha.com - May 13 at 6:39 PM
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine FibroidsMyovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
finance.yahoo.com - May 13 at 6:39 PM
Myovant Sciences Ltd (MYOV) Given Consensus Rating of "Buy" by AnalystsMyovant Sciences Ltd (MYOV) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 10 at 4:10 PM
Zacks: Analysts Anticipate Myovant Sciences Ltd (MYOV) to Post -$1.02 Earnings Per ShareZacks: Analysts Anticipate Myovant Sciences Ltd (MYOV) to Post -$1.02 Earnings Per Share
www.americanbankingnews.com - May 10 at 8:45 AM
Here’s What Hedge Funds Think About Myovant Sciences Ltd. (MYOV)Here’s What Hedge Funds Think About Myovant Sciences Ltd. (MYOV)
finance.yahoo.com - May 2 at 6:31 PM
Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of DirectorsAduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
www.globenewswire.com - April 18 at 6:24 PM
Myovant Sciences is Now Oversold (MYOV)Myovant Sciences is Now Oversold (MYOV)
www.nasdaq.com - April 17 at 5:53 PM
Exact Sciences appoints former Kansas governor, secretary of U.S. Dept. of Health, to its board of directorsExact Sciences appoints former Kansas governor, secretary of U.S. Dept. of Health, to its board of directors
www.bizjournals.com - March 19 at 6:24 PM
Exact Sciences appoints former Kansas governor, HHS secretary Sebelius to its board of directorsExact Sciences appoints former Kansas governor, HHS secretary Sebelius to its board of directors
www.bizjournals.com - March 19 at 6:24 PM
Myovant Sciences LtdMyovant Sciences Ltd
www.bloomberg.com - March 19 at 9:53 AM
Myovant Sciences Ltd. Estimate MomentumMyovant Sciences Ltd. Estimate Momentum
www.nasdaq.com - March 18 at 6:30 PM
Myovant- "Value Creation" in Cancer TreatmentMyovant- "Value Creation" in Cancer Treatment
finance.yahoo.com - February 21 at 5:22 PM
Bullish Two Hundred Day Moving Average Cross - MYOVBullish Two Hundred Day Moving Average Cross - MYOV
www.nasdaq.com - February 13 at 5:36 PM
Myovant Sciences up 12%Myovant Sciences up 12%
seekingalpha.com - February 13 at 5:36 PM
Myovant Sciences: Fiscal 3Q Earnings SnapshotMyovant Sciences: Fiscal 3Q Earnings Snapshot
finance.yahoo.com - February 8 at 9:43 AM
Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
finance.yahoo.com - February 7 at 5:32 PM
Andreas Halvorsen Plunges Into Biotech Company Myovant SciencesAndreas Halvorsen Plunges Into Biotech Company Myovant Sciences
finance.yahoo.com - January 11 at 5:31 PM
Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare ConferenceMyovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 9:34 AM
MYOV Makes Notable Cross Below Critical Moving AverageMYOV Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - November 9 at 4:33 PM
Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018
finance.yahoo.com - November 8 at 4:41 PM
Myovant Strengthens Management Team and Adds New Directors to the BoardMyovant Strengthens Management Team and Adds New Directors to the Board
finance.yahoo.com - November 7 at 9:35 AM
Myovant Sciences (MYOV) Reports Complete Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate CancerMyovant Sciences (MYOV) Reports Complete Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
www.streetinsider.com - October 26 at 4:31 PM
Myovant Sciences completes patient enrollment in Phase 3 HERO trial of relugolixMyovant Sciences completes patient enrollment in Phase 3 HERO trial of relugolix
seekingalpha.com - October 24 at 9:29 AM
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate CancerMyovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
finance.yahoo.com - October 24 at 9:29 AM
Myovants female infertility candidate MVT-602 shows encouraging action in early-stage studyMyovant's female infertility candidate MVT-602 shows encouraging action in early-stage study
seekingalpha.com - October 10 at 4:17 PM
Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual CongressMyovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress
finance.yahoo.com - October 10 at 4:17 PM
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual BleedingMyovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
finance.yahoo.com - October 8 at 8:56 AM
Dermavant Announces Changes to Leadership and Board of DirectorsDermavant Announces Changes to Leadership and Board of Directors
www.prnewswire.com - September 5 at 9:34 AM
Roivant Adds Investigational Therapeutic for the Treatment of Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis to PipelineRoivant Adds Investigational Therapeutic for the Treatment of Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis to Pipeline
www.bizjournals.com - September 5 at 9:34 AM
Roivant Sciences Provides Corporate UpdateRoivant Sciences Provides Corporate Update
www.marketwatch.com - August 28 at 9:26 AM
Myovant Sciences to Participate in Two Upcoming Investor ConferencesMyovant Sciences to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - August 28 at 9:26 AM
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
finance.yahoo.com - August 8 at 9:37 AM
Form 4 Myovant Sciences Ltd. For: Jul 23 Filed by: GUINAN MARKForm 4 Myovant Sciences Ltd. For: Jul 23 Filed by: GUINAN MARK
www.streetinsider.com - July 25 at 9:16 AM
Myovant Sciences fails to hold most of Elagolix approval-stoked gain, shares up 2%Myovant Sciences fails to hold most of Elagolix approval-stoked gain, shares up 2%
seekingalpha.com - July 24 at 4:11 PM
Myovant Sciences announces pricing of common sharesMyovant Sciences announces pricing of common shares
seekingalpha.com - July 14 at 4:49 PM
Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common SharesMyovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares
finance.yahoo.com - July 14 at 4:49 PM
Myovant Sciences Ltd. Announces $75 Million Public Offering of Common SharesMyovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares
finance.yahoo.com - July 11 at 4:25 PM
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel